ArticleAdvances in therapy2026
Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWeight loss and malnutrition are poor prognostic factors in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). In this review, the effect of weight loss and body mass index (BMI) on the decline in forced vital capacity (FVC) was assessed using published secondary analyses of the placebo arms of clinical trials of nintedanib in IPF and PPF, as well as previously unpublished analyses of the INPULSIS trials in IPF.
methodsPublished secondary analyses of placebo arms from clinical trials of nintedanib in IPF and PPF were reviewed. In addition, previously unpublished analyses of pooled INPULSIS trial data in IPF were conducted to evaluate the relationship between baseline BMI, weight loss, and FVC decline.
resultsIn published analyses, both low BMI at baseline and weight loss during treatment were associated with greater decline in FVC. New analyses of INPULSIS data indicated that the effect of weight loss on FVC decline was most pronounced in patients with lower BMI (< 25 kg/m
conclusionIncreased attention to nutrition and management of gastrointestinal side effects to help patients adhere to treatment can improve outcome of treatment for IPF and PPF. CLINICAL TRIAL REGISTRATIONS: ClinicalTrials.gov identifier: NCT02999178 (INBUILD), registered December 19, 2016. CLINICALTRIALS: gov identifiers: NCT01335464 and NCT01335477 (INPULSIS-1 and INPULSIS-2), both registered April 13, 2011.
Indexed as
Identifiers
42766097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.